Metastatic Mucinous Adenocarcinoma of the Prostate with PSA Value of 8.6 ng/mL at 5-Year-Followup after Prostatectomy, Radiotherapy, and Androgen Deprivation | Zendy

Christos Kalaitzis | Zendy; Michael I. Koukourakis | Zendy; Stilianos Giannakopoulos | Zendy; Alexandra Giatromanolaki | Zendy; Efthimios Sivridis | Zendy; Athanasios Bantis | Zendy; Stavros Touloupidis | Zendy

Open Access

Metastatic Mucinous Adenocarcinoma of the Prostate with PSA Value of 8.6 ng/mL at 5-Year-Followup after Prostatectomy, Radiotherapy, and Androgen Deprivation

Author(s) -

Christos Kalaitzis,

Michael I. Koukourakis,

Stilianos Giannakopoulos,

Alexandra Giatromanolaki,

Efthimios Sivridis,

Athanasios Bantis,

Stavros Touloupidis

Publication year - 2014

Publication title -

case reports in urology

Language(s) - English

Resource type - Journals

eISSN - 2090-696X

pISSN - 2090-6978

DOI - 10.1155/2014/218628

Subject(s) - medicine , prostate cancer , prostatectomy , adenocarcinoma , androgen deprivation therapy , prostate , urology , prostate adenocarcinoma , radiation therapy , androgen , presentation (obstetrics) , oncology , cancer , radiology , hormone

. Mucinous adenocarcinoma of the prostate is a rare variant of prostate cancer. Its malignant potential and the clinical course of the affected patients remain, by and large, controversial. No data exist about the course of metastatic mucinous adenocarcinoma of the prostate. Case Presentation . This case report describes the excellent clinical course of a 68-year-old patient with metastatic mucinous adenocarcinoma of the prostate, treated by radical prostatectomy, irradiation, and androgen deprivation. Conclusion . In our case, mucinous adenocarcinoma of the prostate does not appear to behave differently than acinar prostate cancer. Its malignant potential is dependent on its Gleason score.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research